FINWIRES · TerminalLIVE
FINWIRES

GSK's Exdensur Wins Canadian Approval for Severe Asthma, Nasal Polyps

By

GSK (GSK) said Health Canada approved Exdensur for severe eosinophilic asthma, which is driven by elevated white blood cells, and for chronic rhinosinusitis with nasal polyps, a condition that causes blockage and inflammation.

Exdensur is the first long-acting biologic in Canada to offer twice-yearly dosing for these conditions, GSK said Tuesday in a statement.

The approval was supported by late-stage trials showing the drug significantly reduced asthma exacerbations, including those requiring hospitalization or emergency care, and reduced nasal polyp size and obstruction versus placebo.

Price: $52.45, Change: $+0.22, Percent Change: +0.42%

Related Articles

Wire

Adaptive Biotechnologies Weighs Separation of Immune Medicine Unit; Shares Fall After Hours

Adaptive Biotechnologies (ADPT) is evaluating strategic and structural alternatives for its immune medicine segment in a plan to separate the business from its minimal residual disease division.A decision on the separation is expected by year-end, the company said Monday in a statement.Adaptive shares fell 5.6% in after-hours trading.

$ADPT
Wire

High Tide Swings to Fiscal Q2 Profit, Revenue Rises; Shares Gain After Hours

High Tide (HITI) reported fiscal Q2 adjusted earnings late Monday of 0.01 Canadian dollars per diluted share, compared with the loss of C$0.04 a year earlier.Three analysts surveyed by FactSet expected a loss of C$0.02.Revenue in the three months ended April 30 rose to C$179.3 million from C$137.8 million a year ago.Analysts surveyed by FactSet expected C$171.2 million.High Tide shares rose 15% in after-hours trading.

$HITI
Wire

Dave & Buster's Entertainment Fiscal Q1 Adjusted Earnings, Revenue Decline

Dave & Buster's Entertainment (PLAY) reported fiscal Q1 non-GAAP net income late Monday of $0.22 per diluted share, down from $0.76 a year earlier.Analysts polled by FactSet expected $0.56.Revenue for the quarter ended May 5 was $559.2 million, down from $567.7 million a year earlier.Analysts expected $580.6 million.Shares of the company were down about 4% in after-hours trading.

$PLAY